Up to the minute news about Hospitals. We'll find the latest Hospital news so you can chat about here.

Data From Lung Cancer Trial Show Clear Survival Benefit

efficacy, 34 of whom received AS1404 plus chemotherapy while 36 received chemotherapy alone. The trial was conducted at hospitals in France, Germany, Australia and New Zealand. AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets

Sun, 1 Oct 2006 06:50:00 GMT
Post your comments about this story here.